KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medpace Holdings (MEDP) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Medpace Holdings (MEDP) over the last 11 years, with Q4 2025 value amounting to $497.0 million.

  • Medpace Holdings' Cash & Equivalents fell 2575.11% to $497.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $497.0 million, marking a year-over-year decrease of 2575.11%. This contributed to the annual value of $497.0 million for FY2025, which is 2575.11% down from last year.
  • Medpace Holdings' Cash & Equivalents amounted to $497.0 million in Q4 2025, which was down 2575.11% from $285.4 million recorded in Q3 2025.
  • Medpace Holdings' Cash & Equivalents' 5-year high stood at $669.4 million during Q4 2024, with a 5-year trough of $28.3 million in Q4 2022.
  • Its 5-year average for Cash & Equivalents is $282.9 million, with a median of $309.1 million in 2021.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first tumbled by 9387.28% in 2022, then skyrocketed by 120536.56% in 2024.
  • Over the past 5 years, Medpace Holdings' Cash & Equivalents (Quarter) stood at $461.3 million in 2021, then crashed by 93.87% to $28.3 million in 2022, then skyrocketed by 768.38% to $245.4 million in 2023, then surged by 172.74% to $669.4 million in 2024, then decreased by 25.75% to $497.0 million in 2025.
  • Its Cash & Equivalents was $497.0 million in Q4 2025, compared to $285.4 million in Q3 2025 and $46.3 million in Q2 2025.